EUVIMEDEUVIMED entdecken
Crossref

A Bifunctional Lysosome‐Targeting Chimera Nanoplatform for Tumor‐Selective Protein Degradation and Enhanced Cancer Immunotherapy

Yumeng Xing, Jingjing Li, Leyuan Wang, Zhihui Zhu, Jian Yan, Yang Liu, Qi Liu iD

Advanced Materials · 2025-03 · 37 (10)

DOI: 10.1002/adma.202417942 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 31.01.2025. Verfasst von Yumeng Xing und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230032, China. Hauptthemen laut MEDLINE: Lysosomes, Immunotherapy, Nanoparticles, Neoplasms. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Research Project for Anhui Universities, Natural Science Foundation of Anhui Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lysosome‐targeting chimeras (LYTACs) have recently emerged as a promising therapeutic strategy for degrading extracellular and membrane‐associated pathogenic proteins by hijacking lysosome‐targeting receptors. However, the antitumor performance of LYTAC is limited by its insufficient tumor accumulation and nonspecific activation. Additionally, the synergistic effects of LYTACs and other therapeutic modalities are crucial. To address these issues, a bifunctional LYTAC nanoplatform (NLTC) is developed for tumor‐selective protein degradation and enhanced cancer immunotherapy. By rationally controlling the surface composition, the NLTC can effectively transport extracellular or membrane proteins into lysosomes for degradation via cation‐independent mannose 6‐phosphate receptors. With removable surface modification, an NLTC is obtained that efficiently accumulated in tumor tissues and avoided on‐target off‐tumor toxicity. Moreover, the synthesis method of NLTC is generally applicable to various enzymes. Thus, catalase (CAT) is encapsulated with NLTC to synergistically degrade cancer cell surface programmed death ligand‐1 (PD‐L1), relieve the immunosuppressive tumor microenvironment for effective cancer immunotherapy, and significantly inhibit tumor growth, recurrence, and metastasis in B16F10‐bearing mice. This work presents a bifunctional LYTAC nanoplatform that can not only perform tissue‐selective protein degradation but also integrate other therapeutic modalities, providing insights into the design of advanced LYTAC technologies for clinical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LysosomesImmunotherapyNanoparticlesNeoplasmsAnimalsMiceCell Line, TumorHumansProteolysisB7-H1 AntigenCatalaseMice, Inbred C57BL

Stichwörter der Autor:innen

PD‐1/PD‐L1 blockadecancer immunotherapylysosome‐targeting chimeraprotein nanocapsuletumor microenvironment

Substanzen

B7-H1 AntigenCatalase

Autor:innen und Institutionen

  • Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230032, China.
  • School of Pharmacy, Inflammation and Immune-Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei, 230032, China.
  • College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361005, China.
  • Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230032, China.
  • College of Chemistry, Nankai University, Tianjin, 300071, China.

ORCID-Profile: Qi Liu

Förderung

  • National Natural Science Foundation of China
  • Natural Science Research Project for Anhui Universities
  • Natural Science Foundation of Anhui Province
  • Pharmacy Peak Discipline Talent Support Project of Anhui Medical University
  • Research Fund of Anhui Institute of translational medicine

Zitieren

APA

Xing, Y., Li, J., Wang, L., Zhu, Z., Yan, J., Liu, Y., & Liu, Q. (2025). A Bifunctional Lysosome‐Targeting Chimera Nanoplatform for Tumor‐Selective Protein Degradation and Enhanced Cancer Immunotherapy. Advanced Materials, 37(10). https://doi.org/10.1002/adma.202417942

Vancouver

Xing Y, Li J, Wang L, Zhu Z, Yan J, Liu Y, et al. A Bifunctional Lysosome‐Targeting Chimera Nanoplatform for Tumor‐Selective Protein Degradation and Enhanced Cancer Immunotherapy. Advanced Materials. 2025;37(10). doi:10.1002/adma.202417942

BibTeX
@article{Xing2025,
  author = {Xing, Yumeng and Li, Jingjing and Wang, Leyuan and Zhu, Zhihui and Yan, Jian and Liu, Yang and Liu, Qi},
  title = {A Bifunctional Lysosome‐Targeting Chimera Nanoplatform for Tumor‐Selective Protein Degradation and Enhanced Cancer Immunotherapy},
  journal = {Advanced Materials},
  year = {2025},
  volume = {37},
  number = {10},
  doi = {10.1002/adma.202417942}
}
Kostenlos starten →